Anti Emetic Efficacy of Combination of Ramosetron and Premixture of Naloxone With Patient-controlled Analgesia
Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
Postoperative nausea and vomiting (PONV) is one of the most undesirable complications after
general anesthesia, and may lead to increased hospital stay and health care costs. The risk
factors for PONV include sex (female population), nonsmoking status, past history of motion
sickness and/or previous PONV, duration of anesthesia and surgical type (particular
gynecologic surgery) and postoperative use of opioids. The overall incidence of PONV has been
reported to be 30% with considerable variability, but can increase up to 69%- 80% in women
undergoing gynecologic surgery with general anesthesia and morphine-patient controlled
analgesia (PCA). Serotonin receptor antagonists (5-HT3) have been suggested one of the first
line therapies for preventing PONV because of their efficacy and few side effects compared
with other antiemetics. However, despite the use of this treatment, the incidence of PONV has
been reported to be between 48 % and 50%. Naloxone is a drug used to counter the effects of
opioid. It was found that administration of low dose naloxone prevents opioid side effects
such as nausea and pruritus without affecting analgesia or opioid requirements in patient
receiving morphine PCA. It was reported that the use of two antiemetic acting at different
mechanisms is better to prevent PONV than monotherapy.
Therefore, this prospective, randomized, controlled study was designed to investigate the
antiemetic efficacy of combination of ramosetron and premixture of naloxone with morphine PCA
after gynecologic surgery.
Phase:
N/A
Details
Lead Sponsor:
Kyungpook National University Kyungpook National University Hospital